RiverVest Venture Partners related stories
All articles and analysis
VC-backed Allakos goes publicSan Carlos, California-based Allakos, a developer of antibodies that treat various eosinophil and mast cell related diseases, has raised about $128.4 million for its IPO after pricing its over 7.1 million shares at $18 per share. The stock began trading July 19, 2018 on the NASDAQ under the ticker symbol "ALLK." Goldman Sachs and Jefferies LLC are the lead underwriters. Allakos' pre-IPO backers include Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.
- RiverVest to raise $150 mln fourth venture fund
RiverVest Venture Partners has set out to raise a $150 million fourth venture fund, according to a filing with the SEC.
- RiverVest Venture Partners adds two to scientific advisory board
RiverVest Venture Partners has named Dr. Ronald T. Borchardt. and Dr. Jared Rutter to its scientific advisory board. Borchardt is a professor emeritus of pharmaceutical chemistry at the University of Kansas-Lawrence while Rutter is a researcher and professor in the biochemistry department at the University of Utah and an investigator with the Howard Hughes Medical Institute.
- Medical device developer VentureMed procures $15 mln Series B
Toledo, Ohio-based VentureMed Group, a medical device company, has raised $15 million in Series B financing. Endeavour Vision led the round with participation from other investors that included RiverVest Venture Partners.
- Amplyx Pharmaceuticals racks up $67 mln Series C
San Diego-based Amplyx Pharmaceuticals, which is developing antifungal agents that treat life-threatening fungal infections, has raised $67 million in Series C financing. Sofinnova Venture Partners led the round with participation from other investors that included Lundbeckfonden Ventures, Arix Bioscience, Pappas Capital, New Enterprise Associates, RiverVest Venture Partners, 3x5 RiverVest II and BioMed Ventures. In conjunction with the financing, Dr. Anand Mehra, managing partner at Sofinnova Ventures, and Dr. Johan Kördel, senior partner at Lundbeckfonden Ventures, will join the Amplyx board of directors.
- Genoa Pharma raises $62 mln
Genoa Pharmaceuticals Inc said May 15 that it completed a $62 million Series A round of financing led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners. Also participating were Novo AS, RiverVest Venture Partners, and TPG Biotech. Genoa said it named A. Bruce Montgomery, M.D., its CEO, while Mark Surber, Ph.D., the company’s founder and investor, was named chief scientific officer. Genoa, of Seattle, is a biopharmaceutical company focused on developing improved therapies for idiopathic pulmonary fibrosis.
- Adarza BioSystems picks up $17 mln in RiverVest-led round
Rochester, New York and St. Louis, Missouri-based Adarza BioSystems Inc, a developer of label-free biosensor assays and instruments, has raised $17 million in Series C funding. RiverVest Venture Partners led the round.
- RiverVest Venture Partners raises $15m
View the latest capital raises
- RiverVest collects over $55 mln for newest fund
St. Louis, Missouri-based venture firm RiverVest Venture Partners has raised over $55 mln for its 3x5 RiverVest Fund II LP, according to an SEC filing https://www.sec.gov/Archives/edgar/data/1657449/000165744915000001/xslFormDX01/primary_doc.xml The target is $125 million.